Skip to main content
Premium Trial:

Request an Annual Quote

NCI Close to Naming Director of Newly Formed RNAi Research Group


Almost a year after the National Cancer Institute set out to create a new RNAi research group, the institute is close to signing on a director for the program, RNAi News has learned.

The group, according to the NIH, is designed to promote collaboration on RNAi research with investigators from both inside and outside the National Institutes of Health, as well as facilitate translational and clinical cancer research. Specifically, the group is to develop: libraries of validated siRNA sequences against cancer-associated transcripts; resources to help researchers generate single gene knock-down; and high-throughput RNAi knockdown screens for new molecular targets of cancer.

In a posting for the director position, issued in July, the NIH said it was seeking a candidate with a PhD or equivalent in biochemistry, molecular biology, immunology, microbiology, biology, or chemistry, as well as expertise in RNAi and/or siRNA, miRNA, and other processes related to post-transcriptional gene silencing.

All applications were to be received by Aug. 15.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.